美國商業資訊新聞 Interfax Business Wire
大台灣旅遊網2018年7月23日 星期四
東芝記憶體株式會社開發出搭載QLC技術的96層BiCS FLASH™

東京--(美國商業資訊)--記憶體解決方案全球領導者東芝記憶體株式會社(Toshiba Memory Corporation)今日宣布,公司已成功開發出其享有專利的3D快閃記憶體——96層BiCS FLASH™的原型樣品,該產品採用4-bit-per-cell(四階儲存單元,QLC)技術,可將單晶片記憶體的儲存容量提升至最高水準。

此新聞稿包含多媒體內容。完整新聞稿可在以下網址查閱:https://www.businesswire.com/news/home/20180719005280/en/

自9月初起,東芝記憶體株式會社將開始向SSD和SSD控制器製造商交付樣品供其進行評估,預計量產將於2019年啟動。

QLC技術的優點在於將每儲存單元資料的位元數從3位元提升到4位元,實現了儲存容量的顯著提高。該新產品在與Western Digital公司聯合開發的單晶片中實現了1.33 terabit的業界最大儲存容量 [1]

此外,該產品還在採用單一封裝的16晶片堆疊式結構中實現了無與倫比的2.66 TB儲存容量。隨著社群網站的普及和物聯網的發展,行動終端機等設備產生的大量資料不斷增加,即時分析和利用資料的需求預計將大幅增加。因此,需要速度快於HDD且儲存容量更大的儲存裝置,而使用96層程技術的QLC產品即是一種解決方案。

該新元件封裝成型的原型機將在8月6-9日於美國加州聖克拉拉舉行的2018年快閃記憶體高峰會(2018 Flash Memory Summit)上亮相。

未來,東芝記憶體株式會社將繼續提高記憶體的儲存容量和效能,並開發滿足各種市場需求的3D快閃記憶體,包括快速擴張的資料中心儲存裝置市場。

註:
1.資料來源:東芝記憶體株式會社,截至2018年7月20日。

關於東芝記憶體株式會社
作為記憶體解決方案全球領導者,東芝記憶體株式會社致力於快閃記憶體和SSD的開發、生產和銷售。2017年4月,東芝記憶體株式會社從東芝公司完成分割,後者於1987年發明了NAND快閃記憶體。東芝記憶體株式會社開創性地開發出了一系列尖端的記憶體解決方案和服務,豐富了人們的生活,並擴大了社會的視野。該公司創新的3D快閃記憶體技術BiCS FLASH™將對先進智慧型手機、PC、SSD、汽車和資料中心等高密度應用領域儲存裝置的未來產生深遠影響。有關東芝記憶體株式會社的更多詳情,請造訪:https://business.toshiba-memory.com/en-apac/top.html

原文版本可在businesswire.com上查閱:https://www.businesswire.com/news/home/20180719005280/en/

免責聲明:本公告之原文版本乃官方授權版本。譯文僅供方便瞭解之用,煩請參照原文,原文版本乃唯一具法律效力之版本。

聯絡方式:

東芝記憶體株式會社
Kota Yamaji, +81-3-3457-3473
商業規劃部
semicon-NR-mailbox@ml.toshiba.co.jp

採用QLC技術的96層BiCS FLASH(照片:美國商業資訊)

Fri, 20 Jul 2018 18:22:00
FlipNpik對公眾開放其內部銷售,並推出法定貨幣的支付閘道

倫敦和新加坡--(美國商業資訊)--針對當地企業的區塊鏈型社群媒體平臺FlipNpik史無前例地對公眾開放其內部銷售,並讓所有人都有機會分享過去僅對大型投資者提供的特權和紅利。這些實力雄厚的投資者又被稱之為「鯨魚」,通常能夠在ICO(首次代幣發行)的內部銷售階段獲得可觀的分紅。如今,FlipNpik採取顛覆性的措施,排除獲得「鯨魚」分紅所需的大型投資,並為公眾提供FNP (FlipNpik)代幣高達100%的分紅,讓小型投資者能有公平的競爭環境。

此新聞稿包含多媒體內容。完整新聞稿可從以下網址查閱:https://www.businesswire.com/news/home/20180719005283/en/

FlipNpik採用首批法定貨幣支付閘道之一,該閘道使用現金轉帳來支援ICO支付。在公司的幫助下,眾多此前可能從未接觸過加密貨幣,但對其十分感興趣的團體,可輕鬆越過「加密貨幣障礙」。

FlipNpik全球執行長Henri Harland表示:「ICO曾是具有包容性的媒介,只要能夠上網或有錢投資的人士都可以參與。 FlipNpik生態系統致力於推動這一技術的大眾化、合作、價值創造的平等分享,以及包容性。我們一直秉承的宗旨是區塊鏈應用於支持財富的公平分配。」

FlipNpik擁有一支強大的團隊,由數位貨幣、金融和行銷領域經驗豐富的企業家和專家組成。公司提供支援互惠關係的獨特生態系統,為小型企業和社區提供助力。在FlipNpik生態系統中(透過FlipNpik應用程式),中小企業可在消費者的協助下獲得更大的能見度,以及更好的行銷和推廣效果,而消費者支持他們所鍾愛的企業時,將獲得相應的獎勵和FNB代幣。此舉為小型企業帶來雙贏的局面,讓它們能夠與擁有龐大行銷預算的全球供應鏈競爭,同時也為消費者帶來價值。

關於FlipNpik

FlipNpik是首個區塊鏈型合作社群媒體,用戶可在社群媒體貼文支持其鍾愛的當地商店,進而獲得收益。用戶可因張貼和宣傳企業而獲得獎勵,而此舉則有助於強化企業的行銷和能見度。FlipNpik行動應用程式已有iOS和Android系統版本,並已列有在瑞士、英國、愛爾蘭、新加坡、加拿大和法國的企業。https://flipnpik.io

原文版本可在businesswire.com上查閱:https://www.businesswire.com/news/home/20180719005283/en/

免責聲明:本公告之原文版本乃官方授權版本。譯文僅供方便瞭解之用,煩請參照原文,原文版本乃唯一具法律效力之版本。

聯絡方式:

FlipNpik
Henri Harland,執行長
h.harland@flipnpik-ww.com
Skype: Henrij.h22

YourPRstrategist
Cecilia Wong, +65-91826605
cecilia@yourPRstrategist.com

在社群媒體貼文支持當地商店以賺取收益。(圖片:美國商業資訊)

Fri, 20 Jul 2018 18:20:00
戴德梁行收購澳洲Inc RE

這項具有里程碑意義的收購將強化戴德梁行在該地區及全球的資本市場平臺

雪梨--(美國商業資訊)--全球首屈一指的房地產服務公司戴德梁行(Cushman & Wakefield)今天宣佈已完成對Inc RE的收購,後者是專注於商業銷售、收購和投資顧問的頂尖澳洲資本市場公司。該公司團隊將加入戴德梁行資本市場澳洲平臺,並成為該公司全球資本市場網路的一部分。

戴德梁行亞太區執行長Matthew Bouw表示:「我欣然歡迎Inc RE團隊加入戴德梁行。今天宣佈的消息進一步鞏固了我們作為全球首屈一指資本市場公司的地位,展現了我們的品牌和文化吸引頂尖人才的能力。我們將整合全球資本市場專業人士及近期收購的Inc RE,為全球主要市場的客戶創造一流的業績 。」

戴德梁行澳洲資本市場業務將由Inc RE負責人Josh Cullen領導。該團隊包括14名經紀人,專注於機構銷售、國際投資、收購和投資顧問業務。Cullen團隊的其他主要成員包括Rick Butler和首席經紀人Steve Kearney、Mark Hansen等。

澳洲及紐西蘭執行長James Patterson在評論這宗具有里程碑意義的收購時表示:「這宗收購補強了我們在當地的資本市場平臺,並為我們創造了在全國資本市場的發展動力。它為公司加速發展廣泛的商業房地產業務,尤其是資產服務和代理租賃業務提供了機會。它還進一步補強了我們的租戶業務。此項業務擁有70餘家簽約客戶,是全國最強的業務之一。」

戴德梁行新任命的澳洲和紐西蘭國際總監兼資本市場負責人Josh Cullen表示:「本公司的吸引力在於戴德梁行的全球平臺,以及更重要的是它專精於全球資本市場。公司近期新聘用的人員在相對較快的繼任時間內迅速成為美國和歐洲市場的高層。我們希望在亞太地區複製這種成功,繼續鞏固澳洲的業務。隨著房地產投資資金持續全球化,我們認為可以藉此機會建立澳洲客戶和投資產品與全球資金來源之間的關聯。」

除Josh Cullen、Rick Butler、Steve Kearney和Mark Hansen之外,Claire Zouroudis、Charles Long和Lisa Lee也將加入戴德梁行位於雪梨的資本市場業務部。Inc RE過去18個月完成的交易總額達22.5億美元。

編者按

戴德梁行近期的部分全球交易包括紐約市Chelsea Market,24億美元;香港LinkReit Shopping Mall Portfolio,29.5億美元;紐約市One Astor Plaza,19.5億美元;倫敦Walkie Talkie Building (20 Fenchurch St),17億美元;倫敦Leadenhall Building,14.8億美元;香港8 Bay East,12億美元;海南清水灣,9.5億美元;巴黎80-82 Quai Michelet,8.112億美元;廣州環球都會廣場,5.9億美元;新加坡Twenty Anson,3.77億美元。

關於戴德梁行

戴德梁行是全球首屈一指的房地產服務商,將構想付諸行動,為房地產租戶及業主創造超額價值。戴德梁行是全球最大的房地產服務商之一,在70多個國家400個辦事處共有48,000名員工。2017年,公司營業收入為69億美元,核心業務包括資產、設施與專案管理、租賃、資本市場、鑑價及其他服務。 如欲瞭解更多資訊,請造訪www.cushmanwakefield.com或關注Twitter:@CushWake。 

原文版本可在businesswire.com上查閱:https://www.businesswire.com/news/home/20180719005971/en/

免責聲明:本公告之原文版本乃官方授權版本。譯文僅供方便瞭解之用,煩請參照原文,原文版本乃唯一具法律效力之版本。

聯絡方式:

Fergus Ross
董事,Six Degrees
+61 420 980 448
fergus.ross@6-degrees.com.au

Fri, 20 Jul 2018 16:09:00
Poseidon Foundation:利物浦努力在2020年前底成為首個「氣候友好型」城市

• 利物浦希望在2020年底前成為全球首個氣候友好型城市

• 利物浦市政廳將啟動為期一年的試行專案,希望在2018年底前成為首個氣候友好型地方政府

• 市議會超過110%的燃料和能源排放經由Poseidon的創新科技再平衡

英國利物浦--(美國商業資訊)--The Poseidon Foundation (“Poseidon”)與利物浦市政廳簽署開拓性的合作夥伴協議,在2020年底前將利物浦打造為全球首個氣候友好型城市。

市政廳已與Poseidon簽署協定,將其突破性的區塊鏈驅動平臺整合到利物浦的日常運作中。經由透明的作業方式支援基本的森林保護專案,Poseidon的技術可抵消所有產品或服務的碳影響,使個人、組織和政府能夠透過自己的活動來逆轉氣候變遷的影響。

利物浦將在未來12個月試行新的氣候友好型策略,Poseidon也將其業務運作遷至利物浦,以便在此策略中扮演關鍵角色。Poseidon已與利物浦公司BAC Mono密切合作,創造出全球第一台氣候友好型汽車。它還將與當地的學校、大學和企業合作,開發與氣候影響相關的教育課程,在市議會致力於在2030年前將整體碳排放量減少40%的過程中,此將扮演重要角色。這相當於保護1.36億棵樹或33.8萬個足球場,並可在秘魯亞馬遜地區創造超過3,500個工作機會。

此外,利物浦市長將於2018年9月主辦策略性商業高峰會,邀請公司、社會企業和整個城市地區的非營利組織共同探討Poseidon如何能協助各個公司成為氣候友好型企業。

利物浦市議會致力於在2018年底前成為全球首個氣候友好型政府,並最終於2020年底前將利物浦打造為全球首個氣候友好型城市。無論是鐵路、公共浴室、電燈,還是會員圖書館或外用藥,利物浦一直是敢為人先的城市,它現在也將引領英國的永續發展議程。利物浦市議會與Poseidon的合作將成為利物浦首開先河的又一典範,將在10月31日舉行的聯合國世界城市日(UN World Cities Day)向全球其他主要城市展示。

利物浦市長Joe Anderson表示:「我們很高興與Poseidon簽署這項合作夥伴協定,使利物浦與全球氣候友好型專案建立直接的關連。Poseidon的技術屬同類之首,能真正為全球的政府、企業和個人帶來解決方案,幫助逆轉氣候變遷的原因。我很高興這份協議將把這一尖端技術引進我們的城市。

「由於我們提供的所有服務,例如路燈、經營聖喬治廳和體育館等各種房地產物業及我們的車隊等,利物浦市議會留下了大量碳足跡。我們在2030年之前減少40%的碳影響方面已經取得顯著進展,但這還遠遠不夠。Poseidon是一家擁有龐大發展潛力的公司,我們與其合作表示我們可探索重大的新途徑,採行更多措施。」

Poseidon創辦人兼執行長Laszlo Giricz表示:「此次合作不僅對於Poseidon和利物浦而言是開拓性創舉,對全球而言亦是如此。首次有城市利用區塊鏈技術來引領對抗氣候變遷的行動,而不只是再平衡碳足跡。利物浦是英國和全球其他城市的開拓先鋒和光輝榜樣,將展現如何利用科技的力量來應付人類最大的挑戰之一。毋庸置疑,我們的平臺具備全面可擴充性,這是其他城市積極採取行動的時候了。」

編者按

Poseidon代幣銷售目前正在進行中,請在此處登記。

關於Poseidon

Poseidon是一家非營利基金會,致力於透過突破性的方法,幫助每個人重新平衡他們的氣候影響。Poseidon使用區塊鏈技術,例如將碳市場整合到銷售點的交易中,讓消費者在購買日常物品時有機會透過支持世界各地林業保護專案的方式,重新平衡他們選擇的生活方式對氣候的影響。經由為個人、組織和政府提供全面的選項,Poseidon將改變人們與其碳足跡之間的關係,鼓勵關鍵的行為改變,並釋放巨大的碳市場成長潛力,從而有效地應付氣候變遷。

查詢Poseidon詳情,請造訪www.poseidon.eco

關於利物浦市議會

利物浦市議會對減少碳足跡有長期承諾。目前,它在全市2,000條街道安裝了超過1.5萬盞節能白光LED路燈,將路燈能耗降低82%。自2012年以來,利物浦已減少超過55.8萬噸的二氧化碳產量,每年減排7萬噸。市議會持有利物浦交通基礎設施的主要股權,並在利物浦的郵輪碼頭和機場擁有投資資產,目前正監督實施一項計畫以減少市中心公車旅途的70萬閒置英里數。

www.liverpool.gov.uk

原文版本可在businesswire.com上查閱:https://www.businesswire.com/news/home/20180719005057/en/

免責聲明:本公告之原文版本乃官方授權版本。譯文僅供方便瞭解之用,煩請參照原文,原文版本乃唯一具法律效力之版本。

聯絡方式:

Poseidon
Lindsay McCallum
電子郵件:l.mccallum@hawthornadvisors.com
電話:+44 (0) 20 3745 3811

Finn McLaughlan
電子郵件:f.mclaughlan@hawthornadvisors.com
電話:+44 (0) 20 3745 3810

利物浦市議會
Mike Doran -
電子郵件:mike.doran@liverpool.gov.uk
電話:+44 (o) 151 233 0074 / 0780 145 3918

Fri, 20 Jul 2018 13:10:00
Emmaus Life Sciences宣布《新英格蘭醫學雜誌》發表 Endari™(左旋左旋麩醯胺酸口服粉劑)治療鐮狀細胞病3期試驗結果

結果顯示了下列指標的顯著改善:鐮狀細胞危象中位次數減少、入院次數減少、累計住院天數減少、急性胸腔症候群發生率降低

加州托倫斯 -- (美國商業資訊) -- 參閱電子媒體資源 – Emmaus Life Sciences, Inc. (Emmaus)今天宣布,《新英格蘭醫學雜誌》(NEJM)已發表該公司Endari™(左旋麩醯胺酸口服粉劑)48周3期臨床試驗的結果,2017年7月,FDA依據該試驗核准Endari™用於減少成人和5歲及以上兒童鐮狀細胞病患者的急性併發症。

該文報導的結果顯示,與安慰劑組相比,Endari組的鐮狀細胞危象次數少25%,差異有統計學意義;p=0.005(中位3次vs中位4次),入院次數少33%,差異有統計學意義;p=0.005(中位2次vs中位3次)。其他結果顯示,累計住院天數少41%,差異有統計學意義;p=0.02(中位6.5天vs中位11天),急性胸腔症候群(ACS)發生率低60%以上;差異有統計學意義;p=0.003(發生至少一次ACS者,Endari組152例患者中有13例[8.6%],安慰劑組78例中有18例[23.1%])。該臨床研究中最常見不良反應(發生率高於10%)有便秘、噁心、頭痛、腹痛、咳嗽、肢端疼痛、背痛和胸痛。

該論文共同作者、Emmaus執行長、創辦人Yutaka Niihara, MD表示:「Endari是首個獲准用於治療5歲及以上鐮狀細胞病兒童的治療藥物,也是近20年來首個獲准用於成人患者的治療藥物。我們希望透過分享《新英格蘭醫學雜誌》這項具有世界性影響力的權威雜誌發表的資料結果,來幫助提升鐮狀細胞病的知曉度,該病是一種終身患病的遺傳性血液疾病,常見於非洲裔及中南美洲裔,以及中東、亞洲、印度和地中海裔。」

The Sickle Cell Disease Association of America, Inc.總裁兼執行長Beverley Francis-Gibson表示:「美國有數千人罹患鐮狀細胞病。儘管這種危及生命的疾病缺乏療效一致的治癒方法,但患者知曉和有關治療選擇的宣導仍然是鐮狀細胞病群體的重要因素。」

有關3期臨床研究的進一步資訊
此項隨機、雙盲、安慰劑對照、多中心3期試驗評估Endari(每次給藥量為每公斤體重給予0.3克)每天兩次口服與安慰劑對照的有效性和安全性。研究納入鐮狀細胞貧血或鐮狀細胞β0地中海貧血患者,至少5歲,過去1年內有2次或以上疼痛危象史。接受hydroxyurea且劑量在篩檢前保持穩定至少3個月並在48周治療期間繼續使用的患者符合入組條件。合計230例患者(年齡介於5至58歲;53.9%為女性)依2:1比例隨機分配至左旋麩醯胺酸組(152例)或安慰劑組(78例)。

關於鐮狀細胞病
鐮狀細胞病是一種遺傳性血液疾病,特點是產生一種扭曲形態的血紅蛋白,該血紅蛋白可形成聚合物並引起纖維化,導致紅血球僵硬和形態改變,成為鐮刀狀,而非柔軟的圓形。鐮狀細胞病患者可出現致殘性的鐮狀細胞危象發作,即紅血球變僵硬、黏性增大、無法彎曲、阻塞血管。鐮狀細胞危象的組織缺氧可引起劇痛,即組織缺血和炎症。上述事件可導致各類其他不良結果,例如急性胸腔症候群,需要入院。鐮狀細胞病屬於孤兒病,累及近10萬美國患者和數百萬全球患者,具有迫切的未獲滿足的醫療需求。

關於Endari
Endari(左旋麩醯胺酸口服粉劑)是美國食品藥品管理局(FDA)核准的口服處方治療藥物,用於減少成人和5歲及以上兒童鐮狀細胞病患者的急性併發症。Endari於2017年7月獲准,是近20年來首個顯示在遵照醫囑使用時能顯著減少鐮狀細胞病成人患者急性併發症的治療藥物。Endari也是首個獲准在遵照醫囑使用時用於治療5歲及以上鐮狀細胞病患兒急性併發症的治療藥物。Endari已在美國和歐盟獲得孤兒藥認證。

重要安全性資訊
該臨床研究中最常見不良反應(發生率>10%)有便秘、噁心、頭痛、腹痛、咳嗽、肢端疼痛、背痛和胸痛。

導致治療中斷的不良反應包括脾臟腫大、腹痛、消化不良、燒灼感和潮熱紅各1例。

Endari在5歲以下鐮狀細胞病患兒中的安全性和有效性尚未確立。

欲瞭解進一步資訊,請參閱Endari的完整處方資訊:www.ENDARIrx.com/PI

關於Emmaus Life Sciences, Inc.
Emmaus Life Sciences, Inc.是一家生物製藥公司,從事罕見疾病和孤兒病創新治療藥物的發現、開發和商品化。其主導產品Endari在已經完成的鐮狀細胞貧血和鐮狀細胞β0地中海貧血3期臨床試驗中顯示陽性臨床結果,並已獲得FDA核准。請造訪:http://www.emmausmedical.com/

前瞻性陳述
本新聞稿包含1995年《私人證券訴訟改革法案》所定義的前瞻性陳述,這些陳述涉及藥品的研發和潛在商品化。此類前瞻性陳述的依據是當前的預期,含有固有的風險和不確定因素,包括有可能延遲、誤導或改變任何陳述內容的因素,並有可能導致實際結果與當前預期大相徑庭。Emmaus Life Sciences, Inc.向美國證券交易委員遞交的各類報告中,包括Form 10-K年報和Form 10-Q季報,描述了進一步的風險和不確定因素。Emmaus提供的資訊有效期截至本新聞稿發布之日,公司沒有任何責任出於新資訊、未來事件或其他因素來更新任何前瞻性陳述。

參考文獻

Niihara, Y, et al. A Phase 3 Trial of L-Glutamine in Sickle Cell Disease. NEJM to be published 19 July 2018(Niihara, Y等。左旋麩醯胺酸治療鐮狀細胞病3期試驗。《新英格蘭醫學雜誌》將於2018年7月19日發表)

原文版本可在businesswire.com上查閱:https://www.businesswire.com/news/home/20180718005881/en/

免責聲明:本公告之原文版本乃官方授權版本。譯文僅供方便瞭解之用,煩請參照原文,原文版本乃唯一具法律效力之版本。

聯絡方式:

LaVoieHealthScience
Katie Gallagher
辦公室:617-374-8800轉109
手機:617-792-3937
kgallagher@lavoiehealthscience.com

Fri, 20 Jul 2018 13:05:00
Boehringer Ingelheim and Lilly announce Trajenta®’s CARMELINA® cardiovascular outcome trial met its primary endpoint

Trajenta® demonstrates long-term cardiovascular safety in adults with type 2 diabetes

INGELHEIM, Germany & INDIANAPOLIS, Ind.--()--CARMELINA®1 (CArdiovascular safety and Renal Microvascular outcomE with LINAgliptin in patients with type 2 diabetes at high vascular risk) met its primary endpoint, defined as time to first occurrence of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke (3-point MACE), with Trajenta® (linagliptin) demonstrating similar cardiovascular safety compared to placebo. Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced today positive top-line results, which evaluated the impact of treatment with linagliptin vs. placebo on cardiovascular safety on top of standard of care.

The study included 6,979 adults with type 2 diabetes and high cardiovascular risk.1 The majority of patients also had kidney disease, an important risk factor for cardiovascular disease. The overall safety profile of linagliptin in CARMELINA®, including adults with kidney disease, was consistent with previous data and no new safety signal was observed.

People who have diabetes are at an increased risk of cardiovascular disease and chronic kidney disease.2,3 Despite recent advancements in treatment options, cardiovascular disease remains the leading cause of death for people living with diabetes,4 and about two thirds of chronic kidney disease cases are attributable to metabolic conditions, such as diabetes, obesity and hypertension.5,6,7

“CARMELINA® reinforces the long-term clinical safety profile of linagliptin in adults with type 2 diabetes, even in those most vulnerable for vascular complications,” said Waheed Jamal, MD, Corporate Vice President and Head of Cardiometabolic Medicine, Boehringer Ingelheim. “The trial adds important new evidence for patients at high risk for heart and kidney disease, a population that has previously been underrepresented in other cardiovascular outcome trials in diabetes.”

“Linagliptin demonstrated cardiovascular safety in adults with type 2 diabetes and high vascular risk, with no need for dose adjustments regardless of kidney function,” added Jeff Emmick, MD, PhD, Vice President, Product Development, Lilly Diabetes. “CARMELINA® provides confidence in linagliptin as an effective and well-tolerated treatment, with a simple dosing regimen, for adults with type 2 diabetes.”

The full results of CARMELINA® will be presented on 4 October at the 54th European Association for the Study of Diabetes Annual Meeting in Berlin, Germany.

About the Study
CARMELINA® (CArdiovascular safety and Renal Microvascular outcomE with LINAgliptin in patients with type 2 diabetes at high vascular risk) is a multi-national, randomised, double-blind, placebo-controlled clinical trial that involved 6,979 adults with type 2 diabetes from 27 countries at more than 600 sites observed for a median duration of 2.2 years.1 The study was designed to assess the effect of Trajenta® (linagliptin) (5 mg once daily) compared to placebo (both added to standard of care) on cardiovascular outcome in adults with type 2 diabetes and cardiovascular risk, the majority of whom also had kidney disease. This population reflects patients that doctors see in their daily practice. CARMELINA® was led by an academic trial steering committee and the Boehringer Ingelheim and Eli Lilly and Company Diabetes Alliance. Compared to other recently reported outcome trials of dipeptidyl peptidase-4 (DPP-4) inhibitors in type 2 diabetes, CARMELINA® included the highest number of patients with impaired kidney function.*

Standard of care included both glucose lowering agents and cardiovascular drugs (including antihypertensive and lipid lowering agents).

About Trajenta® (linagliptin)
Trajenta® is a one dose, once daily DPP-4-inihibitor that provides significant efficacy in the reduction of blood sugar levels for adults with type 2 diabetes. It can be prescribed for people with type 2 diabetes regardless of age, disease duration, ethnicity, body mass index (BMI), liver and kidney function.8 Trajenta® has the lowest kidney excretion rate of all DPP-4 inhibitors.8,9,10,11,12 It is prescribed at the same dose and has demonstrated proven efficacy regardless of kidney function,8,13,14 making it simple to administer and use.

About our cardiovascular outcome trials
Cardiovascular outcome trials are highly relevant, as cardiovascular disease is a major complication and the leading cause of death in type 2 diabetes. Worldwide, most people with type 2 diabetes die of a cardiovascular event.15 In 2015, Boehringer Ingelheim and Eli Lilly and Company announced results from the landmark cardiovascular outcome trial EMPA-REG OUTCOME® with the SGLT2 inhibitor empagliflozin, which demonstrated a 38% relative risk reduction in cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.†16,17

CARMELINA® is one of two cardiovascular outcome trials with the DPP-4 inhibitor linagliptin. CAROLINA®,18will be the first DPP-4 inhibitor cardiovascular outcome trial to compare commonly used second line treatments - linagliptin and the sulphonylurea glimepiride. This trial includes adults with type 2 diabetes at increased cardiovascular risk, however, the majority did not yet have heart and kidney disease. The study is expected to complete in 2018. CARMELINA® and CAROLINA® will provide the most comprehensive clinical database on the long-term safety profile of a DPP-4-inhibitor in a broad range of adults with type 2 diabetes.

Please click on the following link for ‘Notes to Editors’ and ‘References’: http://www.boehringer-ingelheim.com/press-release/CARMELINA-high-level

* glomerular filtration rate below 30 mL/min/m2

† Adult patients with type 2 diabetes and coronary artery disease, peripheral artery disease, or a history of myocardial infarction or stroke

 

Contacts

Boehringer Ingelheim
Katharina Opitz
Product Communication
Email: press@boehringer-ingelheim.com
Phone: +49 (6132) 77 2012
or
Grant Smith
Manager, Global Business Communications
Lilly Diabetes
Email: grant.smith@lilly.com
Phone: +1 (317) 954 9907

 

Fri, 20 Jul 2018 09:16:00
JPMorgan Chase Bank announces the initial exchange price for the cash-settled exchangeable bonds into Ping An Insurance (Group) Company of China Limited due 2020

LONDON -- (BUSINESS WIRE) --

NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OR TO, OR FOR THE ACCOUNT OR BENEFIT OF, U.S. PERSONS (AS DEFINED IN REGULATION S UNDER THE U.S. SECURITIES ACT OF 1933) OR IN OR INTO JAPAN, THE PEOPLE’S REPUBLIC OF CHINA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW.

Following the placement on 17 July 2018, JPMorgan Chase Bank, N.A. today announces the initial exchange price of the cash-settled exchangeable bonds due 2020 (the “Bonds”) in aggregate principal amount of USD 350 million, referable to H-shares of Ping An Insurance (Group) Company of China Limited (the “Shares”).

The initial exchange price of the Bonds has been set at HKD82.1720, representing a 16% premium over the share reference price of HKD70.8379, which was determined in the manner described in the press announcements released on 17 July 2018.

Settlement and delivery of the Bonds is expected to take place on 20 July 2018.

The Bonds are expected to be rated “Aa3” by Moody’s Investors Services, Inc. (“Moody’s”).

About JPMorgan Chase

JPMorgan Chase & Co. (NYSE: JPM) is a leading global financial services firm with assets of $2.6 trillion and operations worldwide. JPMorgan Chase & Co. is a leader in investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. A component of the Dow Jones Industrial Average, JPMorgan Chase & Co. serves millions of customers in the United States and many of the world's most prominent corporate, institutional and government clients under its J.P. Morgan and Chase brands. Information about JPMorgan Chase & Co. is available at www.jpmorganchase.com.

Further Information
Marie Cheung
Tel.: +852 2800 1303
Email: Marie.W.Cheung@jpmorgan.com

Patrick Burton
Tel.: +44 (0) 207 134 9041
Email: patrick.o.burton@jpmorgan.com

IMPORTANT NOTICE

NO ACTION HAS BEEN TAKEN BY THE ISSUER, THE SOLE BOOKRUNNER OR ANY OF THEIR RESPECTIVE AFFILIATES THAT WOULD PERMIT AN OFFERING OF THE BONDS OR POSSESSION OR DISTRIBUTION OF THIS PRESS RELEASE OR ANY OFFERING OR PUBLICITY MATERIAL RELATING TO THE BONDS IN ANY JURISDICTION WHERE ACTION FOR THAT PURPOSE IS REQUIRED. PERSONS INTO WHOSE POSSESSION THIS PRESS RELEASE COMES ARE REQUIRED BY THE ISSUER AND THE SOLE BOOKRUNNER TO INFORM THEMSELVES ABOUT, AND TO OBSERVE, ANY SUCH RESTRICTIONS.

A CREDIT RATING IS NOT A RECOMMENDATION TO BUY, SELL OR HOLD SECURITIES AND MAY BE SUBJECT TO REVISION, QUALIFICATION, SUSPENSION, REDUCTION OR WITHDRAWAL AT ANY TIME BY THE ASSIGNING RATING AGENCY. THE BONDS ARE EXPECTED TO BE RATED BY MOODY’S AND THERE IS NO ASSURANCE THAT A RATING WILL BE GIVEN OR THAT THE BONDS WILL BE RATED AT ANY TIME. IN ADDITION, CREDIT RATING AGENCIES MAY CHANGE THEIR METHODOLOGY FOR ASSIGNING RATINGS AT ANY TIME. PROSPECTIVE INVESTORS SHOULD EVALUATE ANY RATING OF THE BONDS INDEPENDENTLY OF ANY OTHER RATING OF OTHER SECURITIES OF THE ISSUER OR THE COMPANY OR ANY RATING OF THE ISSUER OR THE COMPANY.

THIS PRESS RELEASE IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES OR TO, OR FOR THE ACCOUNT OR BENEFIT OF, U.S. PERSONS (AS DEFINED IN REGULATION S). ANY TERM SHEET PRODUCED IN CONNECTION WITH THE BONDS SHALL NOT BE AN OFFER TO SELL SECURITIES OR THE SOLICITATION OF ANY OFFER TO BUY SECURITIES, NOR SHALL THERE BE ANY OFFER OF SECURITIES IN ANY JURISDICTION IN WHICH SUCH OFFER OR SALE WOULD BE UNLAWFUL.

THE BONDS DESCRIBED IN THIS PRESS RELEASE ARE NOT REQUIRED TO BE REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR WITH ANY SECURITIES REGULATORY AUTHORITY OF ANY STATE OR OTHER JURISDICTION OF THE UNITED STATES. IN ADDITION, THE BONDS HAVE NOT BEEN REGISTERED UNDER THE REGULATIONS OF THE U.S. COMPTROLLER OF THE CURRENCY (“COMPTROLLER'S REGULATIONS”) RELATING TO SECURITIES OFFERINGS BY NATIONAL BANKS (12 C.F.R. PART 16). THE BONDS MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR UNLESS SUCH TRANSACTION IS EXEMPT FROM, OR NOT SUBJECT TO, SUCH REGISTRATION.

THE BONDS, WHEN OFFERED, WILL BE OFFERED AND SOLD OUTSIDE THE UNITED STATES IN COMPLIANCE WITH REGULATION S, AS SUCH REGULATION IS INCORPORATED INTO THE COMPTROLLER’S REGULATIONS BY 12 C.F.R. SECTION 16.5(G). THE BONDS MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED WITHIN THE UNITED STATES OR TO, OR FOR THE ACCOUNT OR BENEFIT OF, U.S. PERSONS (I) AS PART OF THEIR DISTRIBUTION AT ANY TIME OR (II) UNTIL 40 DAYS AFTER COMPLETION OF THE DISTRIBUTION OF BONDS, EXCEPT IN EITHER CASE IN ACCORDANCE WITH REGULATION S UNDER THE SECURITIES ACT, AS SUCH REGULATION IS INCORPORATED INTO THE COMPTROLLER'S REGULATIONS BY 12 C.F.R. SECTION 16.5(G). TERMS USED ABOVE HAVE THE MEANINGS GIVEN TO THEM BY REGULATION S.

THIS PRESS RELEASE AND THE OFFERING WHEN MADE ARE ONLY ADDRESSED TO, AND DIRECTED IN MEMBER STATES OF THE EUROPEAN ECONOMIC AREA (THE “EEA”), AT PERSONS WHO ARE “QUALIFIED INVESTORS” WITHIN THE MEANING OF ARTICLE 2(1)(E) OF THE PROSPECTUS DIRECTIVE (“QUALIFIED INVESTORS”). FOR THESE PURPOSES, THE EXPRESSION "PROSPECTUS DIRECTIVE" MEANS DIRECTIVE 2003/71/EC, AS AMENDED.

THE BONDS WILL NOT AND MAY NOT BE OFFERED OR SOLD IN HONG KONG, BY MEANS OF ANY DOCUMENT, OTHER THAN (A) TO “PROFESSIONAL INVESTORS” AS DEFINED IN THE SECURITIES AND FUTURES ORDINANCE (CHAPTER 571 OF THE LAWS OF HONG KONG) (THE “SFO”) AND ANY RULES MADE UNDER THAT ORDINANCE; OR (B) IN OTHER CIRCUMSTANCES WHICH DO NOT RESULT IN ANY DOCUMENT BEING A “PROSPECTUS” AS DEFINED IN THE COMPANIES (WINDING UP AND MISCELLANEOUS PROVISIONS) ORDINANCE (CHAPTER 32 OF THE LAWS OF HONG KONG) OR WHICH DO NOT CONSTITUTE AN OFFER TO THE PUBLIC WITHIN THE MEANING OF THAT ORDINANCE. ANY TERM SHEET PRODUCED IN CONNECTION WITH THE BONDS SHALL NOT CONSTITUTE AN ADVERTISEMENT, INVITATION OR DOCUMENT RELATING TO THE BONDS WHICH IS DIRECTED AT, AND THE CONTENTS OF WHICH ARE NOT INTENDED TO BE ACCESSED OR READ BY, THE PUBLIC IN HONG KONG (EXCEPT IF PERMITTED TO DO SO UNDER THE SECURITIES LAWS OF HONG KONG) OTHER THAN WITH RESPECT TO THE BONDS WHICH ARE OR ARE INTENDED TO BE DISPOSED OF ONLY TO PERSONS OUTSIDE HONG KONG OR ONLY TO “PROFESSIONAL INVESTORS” AS DEFINED IN THE SFO AND ANY RULES MADE UNDER THAT ORDINANCE.

THE BONDS HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE FINANCIAL INSTRUMENTS AND EXCHANGE ACT OF JAPAN (ACT NO. 25 OF 1948, AS AMENDED, THE “FINANCIAL INSTRUMENTS AND EXCHANGE ACT”). ACCORDINGLY, THE BONDS MAY NOT BE OFFERED OR SOLD, DIRECTLY OR INDIRECTLY, IN JAPAN OR TO, OR FOR THE BENEFIT OF, ANY RESIDENT OF JAPAN (WHICH TERM AS USED HEREIN MEANS ANY PERSON RESIDENT IN JAPAN, INCLUDING ANY CORPORATION OR OTHER ENTITY ORGANISED UNDER THE LAWS OF JAPAN) OR TO OTHERS FOR RE-OFFERING OR RE-SALE, DIRECTLY OR INDIRECTLY, IN JAPAN OR TO, OR FOR THE BENEFIT OF, ANY RESIDENT OF JAPAN EXCEPT PURSUANT TO AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF, AND OTHERWISE IN COMPLIANCE WITH, THE FINANCIAL INSTRUMENTS AND EXCHANGE ACT AND OTHER RELEVANT LAWS AND REGULATIONS OF JAPAN.

THE BONDS ARE NOT BEING OFFERED OR SOLD AND MAY NOT BE OFFERED OR SOLD, DIRECTLY OR INDIRECTLY, IN THE PEOPLE’S REPUBLIC OF CHINA (FOR SUCH PURPOSES, NOT INCLUDING THE HONG KONG AND MACAU SPECIAL ADMINISTRATIVE REGIONS OR TAIWAN, THE “PRC”), EXCEPT AS PERMITTED BY THE SECURITIES LAWS OF THE PRC.

THE BONDS ARE NOT INTENDED TO BE OFFERED, SOLD OR OTHERWISE MADE AVAILABLE TO AND SHOULD NOT BE OFFERED, SOLD OR OTHERWISE MADE AVAILABLE TO ANY RETAIL INVESTOR IN THE EEA. FOR THESE PURPOSES, A RETAIL INVESTOR MEANS A PERSON WHO IS ONE (OR MORE) OF: (I) A RETAIL CLIENT AS DEFINED IN POINT (11) OF ARTICLE 4(1) OF MIFID II; OR (II) A CUSTOMER WITHIN THE MEANING OF DIRECTIVE 2002/92/EC, WHERE THAT CUSTOMER WOULD NOT QUALIFY AS A PROFESSIONAL CLIENT AS DEFINED IN POINT (10) OF ARTICLE 4(1) OF MIFID II. CONSEQUENTLY, NO KEY INFORMATION DOCUMENT REQUIRED BY REGULATION (EU) NO 1286/2014, AS AMENDED (THE "PRIIPS REGULATION") FOR OFFERING OR SELLING THE BONDS OR OTHERWISE MAKING THEM AVAILABLE TO RETAIL INVESTORS IN THE EEA HAS BEEN PREPARED AND THEREFORE OFFERING OR SELLING THE BONDS OR OTHERWISE MAKING THEM AVAILABLE TO ANY RETAIL INVESTOR IN THE EEA MAY BE UNLAWFUL UNDER THE PRIIPS REGULATION.

IN ADDITION, IN THE UNITED KINGDOM THIS PRESS RELEASE IS BEING DISTRIBUTED ONLY TO, AND IS DIRECTED ONLY AT, QUALIFIED INVESTORS (I) WHO HAVE PROFESSIONAL EXPERIENCE IN MATTERS RELATING TO INVESTMENTS FALLING WITHIN ARTICLE 19(5) OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005, AS AMENDED (THE “ORDER”) AND QUALIFIED INVESTORS FALLING WITHIN ARTICLE 49(2)(A) TO (D) OF THE ORDER, AND (II) TO WHOM IT MAY OTHERWISE LAWFULLY BE COMMUNICATED (ALL SUCH PERSONS TOGETHER BEING REFERRED TO AS “RELEVANT PERSONS”). THIS PRESS RELEASE MUST NOT BE ACTED ON OR RELIED ON (I) IN THE UNITED KINGDOM, BY PERSONS WHO ARE NOT RELEVANT PERSONS, AND (II) IN ANY MEMBER STATE OF THE EEA OTHER THAN THE UNITED KINGDOM, BY PERSONS WHO ARE NOT QUALIFIED INVESTORS. ANY INVESTMENT OR INVESTMENT ACTIVITY TO WHICH THIS PRESS RELEASE RELATES IS AVAILABLE ONLY TO (A) RELEVANT PERSONS IN THE UNITED KINGDOM AND WILL BE ENGAGED IN ONLY WITH RELEVANT PERSONS IN THE UNITED KINGDOM AND (B) QUALIFIED INVESTORS IN MEMBER STATES OF THE EEA (OTHER THAN THE UNITED KINGDOM).

ANY DECISION TO PURCHASE ANY OF THE BONDS SHOULD ONLY BE MADE ON THE BASIS OF AN INDEPENDENT REVIEW BY A PROSPECTIVE INVESTOR OF THE ISSUER’S AND THE COMPANY’S PUBLICLY AVAILABLE INFORMATION. NEITHER THE SOLE BOOKRUNNER NOR ANY OF ITS AFFILIATES ACCEPT ANY LIABILITY ARISING FROM THE USE OF, OR MAKE ANY REPRESENTATION AS TO THE ACCURACY OR COMPLETENESS OF, THIS PRESS RELEASE OR THE ISSUER’S AND THE COMPANY’S PUBLICLY AVAILABLE INFORMATION. THE INFORMATION CONTAINED IN THIS PRESS RELEASE IS SUBJECT TO CHANGE IN ITS ENTIRETY WITHOUT NOTICE UP TO THE ISSUE DATE.

THE SECURITIES ARE NOT READILY LIQUID INSTRUMENTS. THE SOLE BOOKRUNNER OR ANY OF ITS AFFILIATES MAY BUT SHALL HAVE NO OBLIGATION TO MAKE A SECONDARY MARKET FOR THE SALE AND PURCHASE OF THE SECURITIES. ALTHOUGH THE DEALER OR ITS AFFILIATES WILL TRY TO PROVIDE PRICING OR OFFER UNWIND FACILITIES, THERE MAY EXIST A TIME WHEN THERE IS A LACK OF LIQUIDITY OR LOW TRADING VOLUME IN THE MARKET FOR THE SECURITIES, WHICH COULD RESULT IN A DECREASE OF THE MARKET VALUE OF THE SECURITIES. IN THE EVENT THAT THE DEALER OR ITS AFFILIATES MAKES A SECONDARY MARKET, IT IS NOT A COMMITMENT TO PURCHASE ANY SECURITY AT A PARTICULAR TIME OR PRICE AND THE DEALER OR ITS AFFILIATES MAY SUSPEND OR TERMINATE MARKET MAKING AT ANY TIME, AT ITS OWN DISCRETION AND WITHOUT NOTICE TO THE HOLDERS. IF THE SECURITIES ARE EARLY REDEEMED PRIOR TO THE MATURITY DATE OR EARLY REDEMPTION DATE (IF APPLICABLE), THE HOLDER OF A SECURITIES MAY SUFFER A HIGHER LOSS OR SIGNIFICANTLY SMALLER GAIN ON THE PRINCIPAL INVESTED, AND MAY ALSO SUFFER SIGNIFICANT UNWIND COSTS AND WIDE BID OFFER SPREADS. EACH PROSPECTIVE INVESTOR SHOULD PROCEED ON THE ASSUMPTION THAT IT MUST BEAR THE ECONOMIC RISK OF AN INVESTMENT IN THE BONDS OR THE SHARES NOTIONALLY UNDERLYING THE BONDS (TOGETHER WITH THE BONDS, THE “SECURITIES”). NEITHER OF THE ISSUER NOR THE SOLE BOOKRUNNER MAKES ANY REPRESENTATION AS TO (I) THE SUITABILITY OF THE SECURITIES FOR ANY PARTICULAR INVESTOR, (II) THE APPROPRIATE ACCOUNTING TREATMENT AND POTENTIAL TAX CONSEQUENCES OF INVESTING IN THE SECURITIES OR (III) THE FUTURE PERFORMANCE OF THE SECURITIES EITHER IN ABSOLUTE TERMS OR RELATIVE TO COMPETING INVESTMENTS.

THE SOLE BOOKRUNNER IS ACTING ON BEHALF OF THE ISSUER AND NO ONE ELSE IN CONNECTION WITH THE BONDS AND WILL NOT BE RESPONSIBLE TO ANY OTHER PERSON FOR PROVIDING THE PROTECTIONS AFFORDED TO CLIENTS OF THE SOLE BOOKRUNNER OR FOR PROVIDING ADVICE IN RELATION TO THE SECURITIES. IN CONNECTION WITH THE OFFERING OF THE BONDS, THE SOLE BOOKRUNNER AND ANY OF ITS AFFILIATES ACTING AS AN INVESTOR FOR ITS OWN ACCOUNT MAY TAKE UP THE SECURITIES AND IN THAT CAPACITY MAY RETAIN, PURCHASE OR SELL FOR ITS OWN ACCOUNT THE SECURITIES OR ANY OTHER SECURITIES OF THE ISSUER, THE COMPANY OR RELATED INVESTMENTS, MAY OFFER OR SELL THE SECURITIES OR OTHER INVESTMENTS OTHERWISE THAN IN CONNECTION WITH THE OFFERING OF THE BONDS, AND MAY ENTER INTO CONVERTIBLE ASSET SWAPS, CREDIT DERIVATIVES OR OTHER DERIVATIVE TRANSACITONS RELATING TO THE BONDS AND/OR THE UNDERLYING SHARES. AS A RESULT OF SUCH TRANSACTIONS, THE SOLE BOOKRUNNER MAY HOLD LONG OR SHORT POSITIONS IN SUCH BONDS OR DERIVATIVES OR IN THE UNDERLYING SHARES. THE SOLE BOOKRUNNER DOES NOT INTEND TO DISCLOSE THE EXTENT OF ANY SUCH INVESTMENT OR TRANSACTIONS. IN ADDITION, THE SOLE BOOKRUNNER AND ITS SUBSIDIARIES AND AFFILIATES MAY PERFORM SERVICES FOR, OR SOLICIT BUSINESS FROM, THE ISSUER, THE COMPANY OR MEMBERS OF THE ISSUER’S AND THE COMPANY’S RESPECTIVE GROUPS, MAY MAKE MARKETS IN THE SECURITIES OF SUCH PERSONS AND/OR HAVE A POSITION OR EFFECT TRANSACTIONS IN SUCH SECURITIES. EACH POTENTIAL INVESTOR ACKNOWLEDGES THAT THE SOLE BOOKRUNNER AND ITS AFFILIATES MAY FROM TIME TO TIME PERFORM VARIOUS INVESTMENT BANKING AND ADVISORY, BROKERAGE, COMMERCIAL BANKING, FINANCIAL ADVISORY AND FIDUCIARY SERVICES FOR THE COMPANY OR ITS AFFILIATES WHICH MAY HAVE CONFLICTING INTERESTS WITH RESPECT TO ANY POTENTIAL INVESTOR.

EACH OF THE ISSUER AND THE SOLE BOOKRUNNER AND THEIR RESPECTIVE AFFILIATES EXPRESSLY DISCLAIMS ANY OBLIGATION OR UNDERTAKING TO UPDATE, REVIEW OR REVISE ANY STATEMENT CONTAINED IN THIS PRESS RELEASE WHETHER AS A RESULT OF NEW INFORMATION, FUTURE DEVELOPMENTS OR OTHERWISE.

THE BONDS MAY NOT BE PUBLICLY OFFERED IN SWITZERLAND AND WILL NOT BE LISTED ON THE SIX SWISS EXCHANGE (“SIX”) OR ON ANY OTHER STOCK EXCHANGE OR REGULATED TRADING FACILITY IN SWITZERLAND. THIS PRESS RELEASE DOES NOT CONSTITUTE A PROSPECTUS WITHIN THE MEANING OF, AND HAS BEEN PREPARED WITHOUT REGARD TO THE DISCLOSURE STANDARDS FOR ISSUANCE PROSPECTUSES UNDER ART. 652A OR ART. 1156 OF THE SWISS CODE OF OBLIGATIONS OR THE DISCLOSURE STANDARDS FOR LISTING PROSPECTUSES UNDER ART. 27 FF. OF THE SIX LISTING RULES OR THE LISTING RULES OF ANY OTHER STOCK EXCHANGE OR REGULATED TRADING FACILITY IN SWITZERLAND. NEITHER THIS PRESS RELEASE NOR ANY OTHER OFFERING OR MARKETING MATERIAL RELATING TO THE BONDS OR THE OFFERING MAY BE PUBLICLY DISTRIBUTED OR OTHERWISE MADE PUBLICLY AVAILABLE IN SWITZERLAND. NEITHER THIS PRESS RELEASE NOR ANY OTHER OFFERING OR MARKETING MATERIAL RELATING TO THE OFFERING, THE ISSUER, OR THE BONDS HAVE BEEN OR WILL BE FILED WITH OR APPROVED BY ANY SWISS REGULATORY AUTHORITY. IN PARTICULAR, THIS PRESS RELEASE WILL NOT BE FILED WITH, AND THE OFFER OF BONDS WILL NOT BE SUPERVISED BY, THE SWISS FINANCIAL MARKET SUPERVISORY AUTHORITY FINMA (FINMA), AND THE OFFER OF BONDS HAS NOT BEEN AND WILL NOT BE AUTHORISED UNDER THE SWISS FEDERAL ACT ON COLLECTIVE INVESTMENT SCHEMES ("CISA"). THE INVESTOR PROTECTION AFFORDED TO ACQUIRERS OF INTERESTS IN COLLECTIVE INVESTMENT SCHEMES UNDER THE CISA DOES NOT EXTEND TO ACQUIRERS OF BONDS.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180719005370/en/

CONTACT:

JPMorgan Chase & Co.
Marie Cheung, +852 2800 1303
Marie.W.Cheung@jpmorgan.com
or
Patrick Burton, +44 (0) 207 134 9041
patrick.o.burton@jpmorgan.com

Fri, 20 Jul 2018 09:10:00
Tigo發布最先進的無線技術Mesh,作為TS4平臺的新太陽能通訊架構

Mesh使得每個TS4單元都能充當太陽能電池陣列上的信號中繼站,並憑藉近日宣布推出的TAP擴大無線範圍

加州洛斯加托斯--(美國商業資訊)--智慧模組Flex MLPE平臺領域的先鋒企業Tigo®今日宣布推出其新的Mesh通訊架構。這種先進的無線技術可直接轉化為客戶獲益,包括簡化太陽能設計過程和加快試車步驟。Tigo成套解決方案採用簡單但強大的資料擷取技術,以最低的成本涵蓋最廣泛的住宅和商業設施。憑藉Mesh和近日宣布推出的Tigo存取點(TAP),客戶將不再需要解決任何屋頂障礙或方位約束問題。如需瞭解有關Mesh和TAP的更多詳情,可免費註冊Tigo於太平洋夏令時間2018年7月25日(週三)上午10點舉行的「無線是太陽能的未來」(The Future of Solar is Wireless)線上網路研討會。

此新聞稿包含多媒體內容。完整新聞稿可在以下網址查閱:https://www.businesswire.com/news/home/20180718005827/en/

Mesh與TAP、Cloud Connect Advanced (CCA)和UHD-Core TS4單元共同組成完整的Tigo系統。作為讓每個TS4單元都能充當信號中繼站的軟體,Mesh將無線通訊範圍擴展至230英尺(70公尺)。此外,Mesh還允許利用單個TAP,從多達300個TS4單元(約100千瓦系統)或利用單個CCA從多達900個TS4單元(約300千瓦系統)採集資料。最重要的是,Mesh支援TS4單元之間的多通訊路徑,可以最大程度地減少資料封包遺失,提高資料完整性,以及提升高速傳輸可靠性。

Mesh的優勢包括:

  • 輕鬆繞過屋頂或地面安裝的障礙物

 

  • 通訊半徑加大

 

  • 減少必要的元件配件

 

  • 因應困難佈局的智慧通訊路徑

 

  • 架構靈活,適用於不同配件位置的容錯式設計

Tigo軟體開發副總裁Maxym Makhota表示:「Mesh是一項突破性的通訊技術,它使得Tigo的TS4平臺和通訊設備附件成為最靈活、最具成本效益和最強大的全球太陽能電池陣列解決方案。我們很高興能夠與新的TAP同時推出這款軟體,這樣一來,我們的客戶可根據需要以盡可能低的成本建置和維護高效率的系統。」

Mesh必須與Tigo的CCA、TAP(或傳統閘道)和UHD-Core TS4單元 – 綜合型(TS4)、改良型/擴展型(TS4-R)或適用於2個模組的改良型(TS4-R-Duo) – 配合使用。所有產品即日起透過全球經銷商和合作夥伴供貨。有關價格和交貨情況,請致電+1.408.402.0802轉1、寄送電子郵件至sales@tigoenergy.com或造訪www.tigoenergy.com

關於Tigo Energy, Inc.

Tigo是由經驗豐富的技術專家團隊於2007年在矽谷創立的公司。Tigo團隊將獨特的系統級方法與半導體、電力電子和太陽能方面的專業知識相結合,為太陽能產業開發了第一代智慧元件最佳化(Smart Module Optimizer)技術。Tigo的願景是充分利用綜合改良型Flex MLPE及通訊技術來降低太陽能電力成本。透過攜手業界的一級模組和變頻器製造商,Tigo能夠利用最智慧的TS4模組化平臺專注於其主要創新,並充分利用更廣泛的生態系統。Tigo在美國、整個歐洲、拉丁美洲、日本、中國、澳大利亞和中東均設有營運據點。如需瞭解更多資訊,請造訪www.tigoenergy.com

原文版本可在businesswire.com上查閱: https://www.businesswire.com/news/home/20180718005827/en/

免責聲明:本公告之原文版本乃官方授權版本。譯文僅供方便瞭解之用,煩請參照原文,原文版本乃唯一具法律效力之版本。

聯絡方式:

Tigo
Tiffany Douglass, 408-402-0802轉430
行銷部
marketing@tigoenergy.com

Mesh是Tigo的專有軟體,能夠讓每個TS4單元都充當中繼器,並將太陽能電池陣列中眾多不同路徑上的Tigo存取點(TAP)範圍擴展,以更快地取得更可靠的太陽能光電資料。(圖片:美國商業資訊)

Thu, 19 Jul 2018 18:33:00
Universal Laser Systems將3M、威格斯和Dexmet的材料加入其材料資料庫

亞利桑那州斯科茨代爾--(美國商業資訊)--Universal Laser Systems (ULS)宣佈將3M™、威格斯(Victrex®)和Dexmet的材料加入其材料資料庫,該資料庫是最廣泛的雷射材料加工參數儲存庫,涵蓋10瓦到500瓦範圍的材料。

新加入ULS材料資料庫的3M、威格斯和Dexmet材料是專為ULTRA和XLS平臺的雷射加工而添加的,這兩個平臺適用於高準確度和高精確度雷射切割、雷射剝蝕和雷射表面改質。

這些材料包括:

 

  • 3M™極限密封膠帶4412N
  • 3M™導熱矽膠介面墊5516
  • Victrex® APTIV® PEEK薄膜
  • Dexmet PolyGrid® 8PTFE10-125ST膨體聚四氟乙烯
  • Dexmet MicroGrid® AL 25延展鋁材

ULS網站的材料庫還提供雷射加工說明,描述這些材料的雷射材料相互作用的結果,以協助潛在客戶瞭解在其製造、研發和原型製作活動中部署雷射技術的優勢。

關於Universal Laser Systems, Inc.

Universal Laser Systems, Inc. (ULS)是雷射材料加工解決方案的全球製造商,致力於創新以及推動現代CO2和光纖雷射技術的應用。從雷射光源、生產力提升技術、先進軟體和光束傳輸系統的開發,到雷射材料加工科學和應用研究方面的廣泛投資,ULS為其客戶提供最具創新性、成本效益、靈活性和可擴充性的雷射材料加工解決方案,以滿足當今和未來的需求。欲瞭解更多資訊,請造訪www.ulsinc.com/zh

原文版本可在businesswire.com上查閱:https://www.businesswire.com/news/home/20180718005105/en/

免責聲明:本公告之原文版本乃官方授權版本。譯文僅供方便瞭解之用,煩請參照原文,原文版本乃唯一具法律效力之版本。

聯絡方式:

Universal Laser Systems, Inc.
James Rabideau, 480-483-1214
jrabideau@ulsinc.com
www.ulsinc.com/zh

Thu, 19 Jul 2018 14:50:00
22nd Century宣佈可立即執行FDA的尼古丁減量計畫

Reynolds American和菲利普莫里斯「在20年內」無法執行FDA的計畫

紐約州威廉姆斯維爾 -- (美國商業資訊) -- 22nd Century Group, Inc. (NYSE American:XXII) 是一家植物生物科技公司,也是煙草減害和極低尼古丁煙草領域的領袖,公司昨天回應了美國食品暨藥物管理局(FDA)的法規制定通告 (ANPRM),FDA將制定法規以規定所有在美國銷售的香煙僅含有極低或非成癮含量的尼古丁。FDA將在其網站www.regulations.gov上線上張貼公司的回應,相應的追蹤號碼是:1k2-94b8-wdcp。22nd Century對FDA之ANPRM的回應全文目前可在以下網址查閱:www.xxiicentury.com/ANPRM

22nd Century對FDA之ANPRM的公開評論說明FDA的擬議法規要求所有在美國銷售的香煙僅含有極低或非成癮含量的尼古丁,如何得到嚴格的獨立科學的支撐。公司同時表明,就公眾健康的利益而言,規劃中的強制性要求具有高度的實用性和迫切的必要性。

FDA所陳述的極低或非成癮性香煙目標立即可行。自2011年以來,22nd Century已生產並提供數千萬支該公司的極低尼古丁含量(VLNC) SPECTRUM®研究用香煙,用於由美國聯邦政府各部門資助一億多美元經費而進行的無數獨立臨床研究。這些獨立臨床研究結果顯示,改用22nd Century的VLNC SPECTRUM®香煙後,吸煙者:(1)減少吸煙,(2)戒斷症狀減輕,(3)戒煙嘗試增加。上述經同儕審查且已發表的研究為FDA提議尼古丁減量的強制性要求提供了堅實的科學依據。VLNC香煙前景看好,據獨立研究人員估計,FDA限制香煙含有極低或非成癮含量尼古丁的規定實施1年後,約500萬人將停止吸煙,而在FDA計畫實施5年內,1300多萬人將停止吸煙。

為了準備因應FDA新規定的即刻實施,22nd Century已增加公司的VLN™煙草種植量,以便在一個種植季節內即可提供足量的專利VLN™煙草種籽,來種植整個美國煙草業所需的足量VLN™ 煙草。

相反的,Reynolds American(英美煙草公司的分公司)肯定無法匹敵22nd Century的成就並符合極低或非成癮含量煙草香煙的標準。2018年7月13日,Reynolds American旗下RAI Services的資深副總裁Michael Ogden博士在對FDA之ANPRM的回應中解釋道:

在現階段……科技落後於這一重要問題,需要開發其他的方法,可能與傳統育種實務結合使用的方法。RAIS相信,距ANPRM討論的低含量尼古丁煙草標準的商業化生產,業界至少還要20年時間。

 

反之,22nd Century已擁有伯萊煙草和烤煙各品種領域專利技術和獨有VLN™煙草植物組成的廣泛產品陣容,並不斷開發具有改良農藝性狀的VLN™新品種。RAIS在對ANPRM的評論中,承認22nd Century在極低尼古丁含量煙草研製中的領先地位:

「此類產品[極低尼古丁煙草]商業化的困難之處在於:(1)煙草公司目前似乎無法獲得基因組編輯技術(CRISPR-cas9)(2)某些基因工程技術的使用受到各類專利限制(例如,尼古丁合成途徑基因專利幾乎全部被22nd Century Group獨家佔有)。(添加重點突顯)

 

Reynolds American並非是指出跨國煙草公司將需要20年來開發極低尼古丁煙草的首家公司。據Bloomberg Business的Sam Chambers報導,Philip Morris International Inc.產品政策總監Rolf Lutz估計:「要從該公司在歐盟全境銷售的所有香煙中提取尼古丁,需要耗資100億至120億美元。」 Chambers繼續說道,「Lutz表示,基因改造煙草植物可降低該成本,但需要大約20年時間。」(添加重點突顯)

22nd Century Group總裁兼執行長Henry Sicignano, III解釋道:「幸運的是,22nd Century的VLN™技術可立即執行並達成FDA所陳述的極低尼古丁或非成癮性香煙目標。」

為了向所有吸煙者即刻提供VLNC香煙,22nd Century已宣佈,願意對所有感興趣的公司授權使用該公司的VLN™技術和VLN™煙草種籽/植物。22nd Century提供的這一授權機會否定了其他煙草公司任何有關無法執行FDA尼古丁減量強制性要求計畫的爭辯。

Sicignano先生解釋道:「大型煙草公司現在有一個選擇:抗爭、攪局並企圖拖延一百年來最重要的公共衛生創舉,或展現改善客戶健康的真誠承諾。既然22nd Century的VLN™技術已經過驗證,可立即用於授權,我們將拭目以待,哪些大型煙草公司真心在乎吸煙者……哪些公司堅持讓客戶沉溺於最致命性的市售消費品。」

關於22nd Century Group, Inc.

22nd Century是一家植物生物科技公司,專注於運用基因工程和植物育種技術來增加或降低煙草植物中的尼古丁含量和大麻植物中的大麻化學成份含量。公司在煙草領域的主要使命是減少吸煙所致的危害。公司在大麻領域的主要使命是開發用於重要新藥的專利大麻植株和農作物。欲瞭解進一步資訊,請造訪www.xxiicentury.comwww.botanicalgenetics.com

有關前瞻性陳述的注意事項:本新聞稿包含前瞻性資訊,包括所有關於22nd Century Group, Inc.、公司董事或管理人員對本新聞稿內容的計畫、信念或當前預期的非歷史事實陳述,包括但不限於我們未來的營業收入預期。「可能」、「將要」、「將會」、「預期」、「估計」、「預計」、「認為」、「打算」等措辭和類似表達與變化形式,可用於識別前瞻性陳述。我們無法保證未來的結果、活動或業績水準。讀者不應對這些前瞻性陳述寄予不恰當的依賴,這些前瞻性陳述只適用於其發佈當日。在聽取我們未來可能發佈的任何書面或口述的前瞻性陳述時,均應考慮這些注意事項。除非適用法律要求,包括美國證券交易方面的法律,我們不打算更新任何前瞻性陳述,以便使這些陳述反映實際結果、後發事件或情況,或反映預料之外事件的發生。讀者必須仔細審閱和考慮我們在201837日呈報的截至20171231日會計年度10-K表年度報告中的各項披露內容,包括名為「風險因素」的章節,以及我們向美國證券交易委員會遞交的其他各項報告,這些報告試圖向利害關係者說明可能影響公司業務、財務狀況、經營結果和現金流的各項風險和因素。若這些風險或不確定因素中的一項或多項成為事實,或基礎假設證明是不準確的,我們的實際結果可能與期望或預測有實質性的差異。

原文版本可在businesswire.com上查閱:https://www.businesswire.com/news/home/20180717005347/en/

免責聲明:本公告之原文版本乃官方授權版本。譯文僅供方便瞭解之用,煩請參照原文,原文版本乃唯一具法律效力之版本。

聯絡方式:

22nd Century Group
James Vail, 716-270-1523
傳播總監
jvail@xxiicentury.com

Thu, 19 Jul 2018 13:59:00
123456

全球新聞股份有限公司 全球新聞網 TraNews手機新聞
版權所有 大台灣旅遊網 翻用必究 歡迎全頁連結,但禁止擅自轉貼節錄